StockNews.com assumed coverage on shares of Tenax Therapeutics (NASDAQ:TENX – Free Report) in a research note published on Saturday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Tenax Therapeutics Trading Down 2.6 %
NASDAQ TENX opened at $4.14 on Friday. Tenax Therapeutics has a one year low of $2.77 and a one year high of $61.20. The stock has a 50-day moving average of $3.38 and a 200 day moving average of $3.90.
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) EPS for the quarter, topping the consensus estimate of ($1.99) by $0.16. Analysts anticipate that Tenax Therapeutics will post -7.96 earnings per share for the current fiscal year.
Tenax Therapeutics Company Profile
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Further Reading
- Five stocks we like better than Tenax Therapeutics
- The How And Why of Investing in Oil Stocks
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- 3 Stocks to Consider Buying in October
- Lowe’s Stock: Hold Now, Buy it When it Dips
- Manufacturing Stocks Investing
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
